Patricia Inacio, PhD, science writer —

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inacio

Long-term rituximab lowers NMOSD relapse risk, eases disability

Treatment with rituximab significantly reduces the risk of relapse and lessens disability in neuromyelitis optica spectrum disorder (NMOSD) patients with antibodies against aquaporin-4 (AQP4), according to a long-term, retrospective Australian study. Most of the analyzed patients received an initial infusion of rituximab at 1,000 mg, given as two separate…

Rituximab found effective for NMOSD in racially diverse patients

In a racially diverse group of people with neuromyelitis optica spectrum disorder (NMOSD), rituximab worked better to prevent relapses than did oral immunosuppressive therapies, a single-center U.S. study showed. This result was particularly relevant for Black patients — who are usually underrepresented in NMOSD clinical trials but who, the…

Plasma exchange effective in elderly NMOSD patients: Study

Plasma exchange, a blood-cleaning procedure, is safe and helps to ease symptoms in elderly people with neuromyelitis optica spectrum disorder (NMOSD), despite the presence of other health conditions. That finding is from a Chinese study that assessed the safety and efficacy of plasma exchange in elderly NMOSD patients (older…

SPHERES, real-world data registry for NMOSD, enrolls 200 patients

SPHERES, a real-world registry designed to better understand neuromyelitis optica spectrum disorder (NMOSD) — its underlying mechanisms, clinical course, and treatment effects — has reached a milestone of 200 enrolled patients. Standing for Synergy of Prospective Health & Experimental Research for Emerging Solutions in NMOSD, the SPHERES…

‘Double-positive’ NMOSD patient safely treated with ofatumumab

A rare case of neuromyelitis optica spectrum disorder (NMOSD) in a patient positive for antibodies against both aquaporin-4 (AQP4) protein and the myelin oligodendrocyte glycoprotein (MOG) was successfully treated with ofatumumab, a B-cell depleting medication approved for multiple sclerosis (MS), a case study reported. According to its researchers, this case represents…